• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by MedTech Acquisition Corporation (Amendment)

    7/27/23 5:00:26 PM ET
    $MTAC
    Medical Specialities
    Health Care
    Get the next $MTAC alert in real time by email
    SC 13D/A 1 brhc20056547_sc13da.htm SC 13D/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

    MedTech Acquisition Corp

    (Name of Issuer)

    Common Stock - Class A

    (Title of Class of Securities)

    58507N105

    (CUSIP Number of Class of Securities)

    David J. Snyderman
    Magnetar Capital LLC
    1603 Orrington Ave.
    Evanston, Illinois 60201
    (847) 905-4400

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

    July 25, 2023

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 58507N105
    SCHEDULE 13D
    Page 2 of 8
    1
    NAMES OF REPORTING PERSONS
     
     
    Magnetar Financial LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    595,140
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    595,140
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    595,140
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    8.0% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA; OO
     
     
     
     

    (1)
     This percentage calculation is based on a total of 7,394,793 Shares outstanding as of July 13, 2023, as reported in the Issuer’s prospectus on Form 424B3 filed with the SEC on July 18, 2023.


    CUSIP No. 58507N105
    SCHEDULE 13D
    Page 3 of 8
    1
    NAMES OF REPORTING PERSONS
     
     
    Magnetar Capital Partners LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    595,140
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    595,140
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    595,140
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    8.0% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC; OO
     
     
     
     

    (1)
    This percentage calculation is based on a total of 7,394,793 Shares outstanding as of July 13, 2023, as reported in the Issuer’s prospectus on Form 424B3 filed with the SEC on July 18, 2023.
     

    CUSIP No. 58507N105
    SCHEDULE 13D
    Page 4 of 8
    1
    NAMES OF REPORTING PERSONS
     
     
    Supernova Management LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    595,140
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    595,140
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    595,140
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    8.0% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC; OO
     
     
     
     

    (1)
    This percentage calculation is based on a total of 7,394,793 Shares outstanding as of July 13, 2023, as reported in the Issuer’s prospectus on Form 424B3 filed with the SEC on July 18, 2023.


    CUSIP No. 58507N105
    SCHEDULE 13D
    Page 5 of 8
    1
    NAMES OF REPORTING PERSONS
     
     
    David J. Snyderman
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    595,140
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    595,140
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    595,140
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    8.0% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC; IN
     
     
     
     

    (1)
    This percentage calculation is based on a total of 7,394,793 Shares outstanding as of July 13, 2023, as reported in the Issuer’s prospectus on Form 424B3 filed with the SEC on July 18, 2023.


    CUSIP No. 58507N105
    SCHEDULE 13D
    Page 6 of 8
    SCHEDULE 13D

    Explanatory Note: This Amendment No. 3 (“Amendment No. 3”) amends and supplements the original Schedule 13D filed on December 22, 2022 (the “Original Schedule 13D”), as amended and supplemented by Amendment No. 1 filed on February 9, 2023 and Amendment No. 2 filed on June 15, 2023 (collectively, the “Schedule 13D”) relating to shares of Class A common stock, par value $0.0001 per share (the “Shares”), of MedTech Acquisition Corp, a company incorporated in Delaware (the “Issuer”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
     
    ITEM 4.
    PURPOSE OF TRANSACTION

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

    Since the filing of Amendment No. 2 on June 15, 2023, the Reporting Persons sold 104,865 Shares between June 15, 2023 and July 26, 2023, which consisted of 58,575 Shares sold for the benefit of Constellation Master Fund, 7,837 Shares sold for the benefit of Lake Credit Fund, 16,230 Shares sold for the benefit of Structured Credit Fund, 19,723 Shares sold for the benefit of Xing He Master Fund, and 2,500 Shares sold for the benefit of Purpose Fund – T.

    ITEM 5.
    INTEREST IN SECURITIES OF THE ISSUER

    Item 5(a)-(c) of the Schedule 13D is hereby amended and supplemented as follows:

    (a), (b) As of July 26, 2023, each of the Reporting Persons may be deemed to have beneficial ownership, shared voting power and shared dispositive power with regard to 595,140 Shares, representing approximately 8.0% of the total number of Shares outstanding. This amount consists of:
    (i) 332,472 Shares held for the benefit of Constellation Master Fund,
    (ii) 3 Shares held for the benefit of a separately managed account,
    (iii) 1 Share held for the benefit of Healthcare Master Fund,
    (iv) 44,438 Shares held for the benefit of Lake Credit Fund,
    (v) 92,113 Shares held for the benefit of Structured Credit Fund,
    (vi) 111,944 Shares held for the benefit of Xing He Master Fund,
    (vii) 1 Share held for the benefit of a separately managed account,
    (viii) 14,168 Shares held for the benefit of Purpose Fund – T.

    The foregoing beneficial ownership percentage is based on a total of 7,394,793 Shares outstanding as of July 13, 2023, as reported in the Issuer’s prospectus on Form 424B3 filed with the SEC on July 18, 2023.

    (c) The response to Item 4 of this Amendment No. 3 is incorporated herein by reference.  Except as set forth in Schedule A and the response to Item 4 of this Amendment No. 3, the Reporting Persons had no transactions in the Shares since the most recent filing of Schedule 13D (Amendment No. 2) on June 15, 2023.


    CUSIP No. 58507N105
    SCHEDULE 13D
    Page 7 of 8
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 27, 2023
       
         
     
    MAGNETAR FINANCIAL LLC
         
     
    By: Magnetar Capital Partners LP, its Sole Member
         
     
    By:
    /s/ Hayley A. Stein
       
    Name:
    Hayley A. Stein
       
    Title:
    Attorney-in-Fact for David J. Snyderman, Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP
         
     
    MAGNETAR CAPITAL PARTNERS LP
         
     
    By:
    /s/ Hayley A. Stein
       
    Name:
    Hayley A. Stein
       
    Title:
    Attorney-in-Fact for David J. Snyderman, Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP
         
     
    SUPERNOVA MANAGEMENT LLC
         
     
    By:
    /s/ Hayley A. Stein
       
    Name:
    Hayley A. Stein
       
    Title:
    Attorney-in-Fact for David J. Snyderman, Manager
         
     
    /s/ Hayley A. Stein
     
    Hayley A. Stein
      Title: Attorney-in-Fact for David J. Snyderman


    CUSIP No. 58507N105
    SCHEDULE 13D
    Page 8 of 8
    SCHEDULE A

    Funds

    Date
    Number of Shares Sold
    Price Per Share($) (1)(2)
    7/25/2023
    50,001
    $10.7550 (3)
    7/26/2023
    54,864
    $10.7263 (4)

    (1) Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of Shares sold at each separate price will be provided.

    (3) Reflects a weighted average sale price of $10.7550 per Share, at prices ranging from $10.75 to $10.76 per Share.

    (4) Reflects a weighted average sale price of $10.7263 per Share, at prices ranging from $10.70 to $10.80 per Share.



    Get the next $MTAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

    Advances TriSalus' Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma Provides Cash Runway through Mid-2024 to Fund Key Milestones TriSalus' Common Stock Expected to Begin Trading on the Nasdaq under Symbol "TLSI" on August 11, 2023 TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tu

    8/10/23 4:05:00 PM ET
    $MTAC
    Medical Specialities
    Health Care

    MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

    MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or the "Company") today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the "Business Combination") with TriSalus Life Sciences ("TriSalus"). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time on August 8, 2023. The Special Meeting will still be held virtually via webcast, and stockholders may attend and participate online by visiting https://www.cstproxy.com/medtechacquisition/sm2023. Participants will be able to li

    8/2/23 5:00:00 PM ET
    $MTAC
    Medical Specialities
    Health Care

    TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

    New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment and decreased circulating tumor DNA (ctDNA) levels TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (NASDAQ:MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pressure-Enabled Regional Immuno-Oncology (PERIO-01) (NCT04935229) cl

    6/12/23 7:00:00 AM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    SEC Filings

    View All

    SEC Form 424B3 filed by MedTech Acquisition Corporation

    424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:23:14 PM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form 424B3 filed by MedTech Acquisition Corporation

    424B3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:21:58 PM ET
    $MTAC
    Medical Specialities
    Health Care

    MedTech Acquisition Corporation filed SEC Form 8-K: Leadership Update

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/25/24 5:19:33 PM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:44:45 PM ET
    $MTAC
    Medical Specialities
    Health Care

    Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:42:18 PM ET
    $MTAC
    Medical Specialities
    Health Care

    Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/14/24 6:39:58 PM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

    TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company"), an oncology company in the process of going public through a business combination transaction (the "Business Combination") with MedTech Acquisition Corporation (NASDAQ:MTAC) ("MedTech" or "MTAC"), today announced that James "Jim" Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr. Alecxih brings to TriSalus more than 30 years of experience in product development, launch and marketing strategies. His responsibilities will include overseeing the growth and development of TriSalus' TriNav® Infusion System ("TriNav®"), including device engineering, device quality, sales, marketing, a

    2/21/23 7:00:00 AM ET
    $MTAC
    Medical Specialities
    Health Care

    $MTAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/29/23 8:00:07 AM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/23/23 12:02:13 PM ET
    $MTAC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by MedTech Acquisition Corporation

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    8/22/23 8:15:18 AM ET
    $MTAC
    Medical Specialities
    Health Care